Cohance Lifesciences Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Low debt relative to equity (D/E 0.1x)
Concerns
- Premium to sector peers (P/E 160x vs industry 50.2x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
COHANCE · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 60.00% | 50.10% | 50.10% | 50.10% | 50.10% | 50.10% |
| FII | 10.14% | 9.54% | 9.80% | 10.70% | 10.84% | 11.05% |
| DII | 15.94% | 17.24% | 17.42% | 16.95% | 16.67% | 16.60% |
| Public | 13.93% | 23.11% | 22.67% | 22.26% | 22.37% | 22.24% |
| Govt | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
To consider and approve the financial results for the period ended Jun 30, 2026
Annual General Meeting
Annual General Meeting
Latest News
All newsCohance Lifesciences completes USFDA inspection.
*Cohance Lifesciences completes USFDA inspection.* The company has announced the successful completion of a USFDA inspection at its facility. This regulatory milestone indicates compliance readiness for export markets. **No observations or adverse findings** were reported during the audit. 📊 *STOCKS:* $COHANCE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Regulatory
Cohance Lifesciences to host investor meet
*Cohance Lifesciences to host an analyst and institutional investor meet.* The event aims to provide updates on company performance and strategy. No financial figures or major announcements were disclosed. The schedule for the meet will be shared separately. 📊 *STOCKS:* $COHANCE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Cohance Lifesciences receives ESG rating from Crisil
*Cohance Lifesciences receives ESG rating from Crisil.* Crisil ESG Ratings & Analytics Limited has assigned an ESG score to Cohance Lifesciences Limited. The rating reflects the company’s environmental, social, and governance practices. This development may interest long-term investors focused on sustainable investing. 📊 *STOCKS:* $COHANCELIFE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Cohance Lifesciences to host analyst and investor meet.
*Cohance Lifesciences to host an analyst and institutional investor meet.* This event aims to provide updates on company strategy and performance. Such meets typically result in increased investor visibility but no immediate business changes. No financial figures or major announcements were disclosed. 📊 *STOCKS:* $COHANCE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹619 Cr 13.6% | ₹545 Cr 2.0% | ₹556 Cr 1.3% | ₹549 Cr 34.6% | ₹840 Cr 24.3% | ₹676 Cr 11.9% | ₹604 Cr 23.8% | ₹488.08 Cr |
| Op. Profit | ₹99 Cr 4.2% | ₹95 Cr 21.5% | ₹121 Cr 8.0% | ₹112 Cr 51.1% | ₹229 Cr 3.4% | ₹237 Cr 15.6% | ₹205 Cr 63.9% | ₹125.1 Cr |
| OPM | 16.0% 11.1% | 18.0% 18.2% | 22.0% 10.0% | 20.0% 25.9% | 27.0% 22.9% | 35.0% 2.9% | 34.0% 32.7% | 25.6% |
| Net Profit | ₹8 Cr 72.4% | ₹29 Cr 56.1% | ₹66 Cr 43.5% | ₹46 Cr 60.7% | ₹117 Cr 23.5% | ₹153 Cr 10.9% | ₹138 Cr 83.1% | ₹75.37 Cr |
| EPS (₹) | 0.51 46.9% | 0.96 50.5% | 1.94 51.6% | 1.28 72.9% | 4.73 21.3% | 6.01 10.5% | 5.44 83.8% | 2.96 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.3K Cr 13.0% | ₹2.6K Cr 148.1% | ₹1.1K Cr 21.6% | ₹1.3K Cr 1.5% | ₹1.3K Cr 30.7% | ₹1.0K Cr 21.1% | ₹834 Cr 120.6% | ₹378 Cr |
| Expenses | ₹1.8K Cr 1.7% | ₹1.8K Cr 180.8% | ₹645 Cr 15.8% | ₹766 Cr 3.8% | ₹738 Cr 30.2% | ₹567 Cr 26.3% | ₹449 Cr 118.0% | ₹206 Cr |
| Op. Profit | ₹427 Cr 46.4% | ₹797 Cr 96.3% | ₹406 Cr 29.3% | ₹574 Cr 1.4% | ₹582 Cr 31.4% | ₹443 Cr 15.1% | ₹385 Cr 123.8% | ₹172 Cr |
| OPM | 19.0% 38.7% | 31.0% 20.5% | 39.0% 9.3% | 43.0% 2.3% | 44.0% 0.0% | 44.0% 4.3% | 46.0% 2.2% | 45.0% |
| Other Income | ₹4 Cr 92.5% | ₹53 Cr 14.5% | ₹62 Cr 34.8% | ₹46 Cr 65.4% | ₹133 Cr 95.6% | ₹68 Cr 3.0% | ₹66 Cr 6500.0% | ₹1 Cr |
| Interest | ₹37 Cr 9.8% | ₹41 Cr 485.7% | ₹7 Cr 46.2% | ₹13 Cr 44.4% | ₹9 Cr 25.0% | ₹12 Cr 47.8% | ₹23 Cr 666.7% | ₹3 Cr |
| Depreciation | ₹187 Cr 12.0% | ₹167 Cr 203.6% | ₹55 Cr 14.6% | ₹48 Cr 23.1% | ₹39 Cr 21.9% | ₹32 Cr 33.3% | ₹24 Cr 100.0% | ₹12 Cr |
| PBT | ₹207 Cr 67.8% | ₹643 Cr 58.4% | ₹406 Cr 27.5% | ₹560 Cr 16.2% | ₹668 Cr 42.7% | ₹468 Cr 15.6% | ₹405 Cr 156.3% | ₹158 Cr |
| Tax % | 27.0% 8.0% | 25.0% 3.8% | 26.0% 3.7% | 27.0% 15.6% | 32.0% 39.1% | 23.0% 4.5% | 22.0% 29.0% | 31.0% |
| Net Profit | ₹150 Cr 69.0% | ₹484 Cr 61.3% | ₹300 Cr 27.0% | ₹411 Cr 9.5% | ₹454 Cr 25.4% | ₹362 Cr 14.2% | ₹317 Cr 190.8% | ₹109 Cr |
| EPS (₹) | 4.68 75.5% | 19.14 62.2% | 11.8 27.0% | 16.16 9.4% | 17.83 25.3% | 14.23 14.3% | 12.45 | — |
| Div Payout | 0.0% | 0.0% | 0.0% 100.0% | 37.0% 32.1% | 28.0% 100.0% | 14.0% 30.0% | 20.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||
| Equity Capital | ₹38 Cr 52.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 92.3% | ₹13 Cr | ₹0 Cr |
| Reserves | ₹3.9K Cr 6.9% | ₹3.6K Cr 78.9% | ₹2.0K Cr 18.4% | ₹1.7K Cr 13.8% | ₹1.5K Cr 30.0% | ₹1.2K Cr 38.8% | ₹832 Cr 43.9% | ₹578 Cr |
| Borrowings | ₹400 Cr 17.7% | ₹486 Cr 647.7% | ₹65 Cr 7.1% | ₹70 Cr 27.8% | ₹97 Cr 32.2% | ₹143 Cr 23.1% | ₹186 Cr 124.1% | ₹83 Cr |
| Other Liabilities | ₹1.4K Cr 5.1% | ₹1.3K Cr 875.4% | ₹138 Cr 13.8% | ₹160 Cr 22.0% | ₹205 Cr 35.8% | ₹151 Cr 6.3% | ₹142 Cr 15.4% | ₹123 Cr |
| Total Liabilities | ₹5.7K Cr 4.5% | ₹5.5K Cr 143.1% | ₹2.3K Cr 14.6% | ₹2.0K Cr 7.4% | ₹1.8K Cr 24.2% | ₹1.5K Cr 25.7% | ₹1.2K Cr 49.8% | ₹783 Cr |
Assets | ||||||||
| Fixed Assets | ₹3.4K Cr 8.4% | ₹3.1K Cr 363.7% | ₹670 Cr 1.1% | ₹663 Cr 24.2% | ₹534 Cr 21.1% | ₹441 Cr 23.5% | ₹357 Cr 31.7% | ₹271 Cr |
| CWIP | ₹178 Cr 46.7% | ₹334 Cr 86.6% | ₹179 Cr 8.5% | ₹165 Cr 450.0% | ₹30 Cr 68.8% | ₹96 Cr 5.9% | ₹102 Cr 8.1% | ₹111 Cr |
| Investments | ₹529 Cr 57.0% | ₹337 Cr 62.7% | ₹904 Cr 68.7% | ₹536 Cr 10.4% | ₹598 Cr 10.3% | ₹542 Cr 60.4% | ₹338 Cr 4728.6% | ₹7 Cr |
| Other Assets | ₹1.7K Cr 2.9% | ₹1.7K Cr 239.7% | ₹501 Cr 16.6% | ₹601 Cr 9.9% | ₹667 Cr 68.9% | ₹395 Cr 5.1% | ₹376 Cr 4.6% | ₹394 Cr |
| Total Assets | ₹5.7K Cr 4.5% | ₹5.5K Cr 143.1% | ₹2.3K Cr 14.6% | ₹2.0K Cr 7.4% | ₹1.8K Cr 24.2% | ₹1.5K Cr 25.7% | ₹1.2K Cr 49.8% | ₹783 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹368 Cr 45.3% | ₹673 Cr 88.0% | ₹358 Cr 21.7% | ₹457 Cr 38.5% | ₹330 Cr 13.8% | ₹383 Cr 5.9% | ₹407 Cr 714.0% | ₹50 Cr |
| Investing CF | ₹-251 Cr 35.3% | ₹-388 Cr 7.2% | ₹-362 Cr 85.6% | ₹-195 Cr 43.4% | ₹-136 Cr 56.3% | ₹-311 Cr 24.7% | ₹-413 Cr 535.4% | ₹-65 Cr |
| Financing CF | ₹-165 Cr 49.5% | ₹-327 Cr 2235.7% | ₹-14 Cr 94.2% | ₹-242 Cr 55.1% | ₹-156 Cr 105.3% | ₹-76 Cr 1185.7% | ₹7 Cr 73.1% | ₹26 Cr |
| Net Cash Flow | ₹-48 Cr 14.3% | ₹-42 Cr 133.3% | ₹-18 Cr 190.0% | ₹20 Cr 45.9% | ₹37 Cr 840.0% | ₹-5 Cr 600.0% | ₹1 Cr 90.9% | ₹11 Cr |
| Free Cash Flow | ₹169 Cr 52.7% | ₹357 Cr 16.3% | ₹307 Cr 79.5% | ₹171 Cr 32.9% | ₹255 Cr 6.3% | ₹272 Cr 10.5% | ₹304 Cr 5166.7% | ₹-6 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 110d 1.9% | 108d 134.8% | 46d 53.3% | 30d 53.8% | 65d 75.7% | 37d 27.5% | 51d 64.1% | 142d |
| Inventory Days | 310d 48.3% | 209d 22.0% | 268d 3.9% | 279d 7.7% | 259d 6.6% | 243d 12.6% | 278d 50.0% | 556d |
| Days Payable | 157d 30.8% | 120d 144.9% | 49d 22.2% | 63d 35.1% | 97d 3.0% | 100d 11.5% | 113d 40.5% | 190d |
| Cash Conv. Cycle | 263d 33.5% | 197d 25.7% | 265d 7.3% | 247d 8.3% | 228d 26.7% | 180d 17.1% | 217d 57.4% | 509d |
| Working Capital Days | 133d 25.5% | 106d 7.8% | 115d 16.2% | 99d 8.3% | 108d 92.9% | 56d 12.5% | 64d 68.8% | 205d |
| ROCE | 6.0% 71.4% | 21.0% 10.5% | 19.0% 40.6% | 32.0% 22.0% | 41.0% 2.5% | 40.0% 20.0% | 50.0% | — |
Source: Screener.in · Lower days = better efficiency
About Cohance Lifesciences Limited
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]
HealthcarePharmaceuticals & Biotechnology